# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-09-094601
Filing Date
2009-04-30
Accepted
2009-04-30 16:55:55
Documents
5
Effectiveness Date
2009-04-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE ADDITIONAL MATERIALS | ddefa14a.htm | DEFA14A | 38178
2 | GRAPHIC | g60243g08v07.jpg | GRAPHIC | 135326
3 | GRAPHIC | g60243g15j66.jpg | GRAPHIC | 215019
4 | GRAPHIC | g60243g53o07.jpg | GRAPHIC | 141498
5 | GRAPHIC | g60243g54v54.jpg | GRAPHIC | 181974
| Complete submission text file | 0001193125-09-094601.txt |  | 968746

Mailing Address 8001 ARISTA PLACE SUITE 200 BROOMFIELD CO 80021
Business Address 8001 ARISTA PLACE SUITE 200 BROOMFIELD CO 80021 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 09784671
SIC: 2835 In Vitro & In Vivo Diagnostic Substances